{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T23:35:27Z","timestamp":1788478527748,"version":"build-2803163510"},"reference-count":59,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"20","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5,16]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors bring hope to cancer patients but may also lead to severe immune-related adverse events (irAEs). Although irAEs during treatment are well-characterized, delayed immune-related events (DIRE) remain underreported. Here, we report a case of sintilimab-induced delayed immune-related diabetes mellitus, accompanied by ICI-related thyroid disease (ICI-TD). Cases involving both ICI-TD and ICI-related diabetes mellitus (ICI-DM) are also relatively rare. This study systematically aggregates dual endocrine irAEs to provide valuable insights for clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>A 60-year-old Chinese male diagnosed with gastric adenocarcinoma received a multimodal treatment regimen consisting of sintilimab, chemotherapy, and apatinib. He completed 3 cycles of chemotherapy and 4 cycles of sintilimab. Due to disease progression, sintilimab was discontinued, but apatinib was continued for an additional 1 month. No further antitumor therapy was administered afterward. Four months later, he was admitted to the emergency department due to persistent nausea, vomiting, and abdominal pain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>Thyroid dysfunction induced by sintilimab was identified during treatment. His laboratory tests contributed to the diagnosis of diabetes ketoacidosis. Fulminant type 1 diabetes mellitus attributed to sintilimab met diagnostic criteria: plasma glucose 42.01 mmol\/L, glycated hemoglobin 7.5%, C-peptide &lt;0.02 \u00b5g\/L, and negative islet autoantibodies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>Levothyroxine replacement therapy was initiated for hypothyroidism, whereas diabetes ketoacidosis during hospitalization required intensive insulin therapy combined with fluid resuscitation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>The patient exhibited persistent blood glucose fluctuations during hospitalization, including 2 hypoglycemic episodes. Post-treatment stabilization required basal-bolus insulin at discharge, with continued levothyroxine for hypothyroidism.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>We report a rare case of concurrent ICI-TD and ICI-DM following sintilimab therapy. This case underscores the potential for DIRE, with onset occurring months posttreatment. Combined with a systematic review of existing cases, this study provides critical insights into surveillance strategies and pathogenesis of irAEs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000042490","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T14:00:42Z","timestamp":1747836042000},"page":"e42490","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Sintilimab-induced diabetes mellitus and thyroid dysfunction in patient with gastric adenocarcinoma: A case report and literature review"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8985-3234","authenticated-orcid":false,"given":"Ying","family":"Zan","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Zibo Central Hospital, Zibo, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yedong","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Zibo Central Hospital, Zibo, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxue","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Zhangdian Traditional Chinese Medicine Hospital, Zibo, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolu","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of pharmacy, Jinshan Town Health Center, Zibo, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jigang","family":"Si","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Zibo Central Hospital, Zibo, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260811","first-page":"e35276","article-title":"A case of pembrolizumab-induced diabetic ketoacidosis and hyperthyroidism in a patient with recurrent esophageal adenocarcinoma.","volume":"15","author":"Salangsang","year":"2023","journal-title":"Cureus"},{"key":"R2-20260811","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2337\/dbi18-0002","article-title":"Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors.","volume":"67","author":"Stamatouli","year":"2018","journal-title":"Diabetes"},{"key":"R3-20260811","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.2337\/dc22-2202","article-title":"Risk factors and characteristics of checkpoint inhibitor-associated autoimmune diabetes mellitus (CIADM): a systematic review and delineation from type 1 diabetes.","volume":"46","author":"Wu","year":"2023","journal-title":"Diabetes Care"},{"key":"R4-20260811","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s40425-019-0645-6","article-title":"Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance.","volume":"7","author":"Couey","year":"2019","journal-title":"J ImmunoTher Cancer"},{"key":"R5-20260811","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2024\/4662803","article-title":"A case in which HLA-DR4 is involved in the development of complex immune-related endocrinological adverse events following combination therapy with nivolumab and ipilimumab.","volume":"2024","author":"Kidawara","year":"2024","journal-title":"Case Rep Endocrinol"},{"key":"R6-20260811","doi-asserted-by":"crossref","first-page":"1366335","DOI":"10.3389\/fimmu.2024.1366335","article-title":"Challenges in autoimmune polyendocrine syndrome type 2 with the full triad induced by anti-programmed cell death 1: a case report and review of the literature.","volume":"15","author":"Pan","year":"2024","journal-title":"Front Immunol"},{"key":"R7-20260811","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.12998\/wjcc.v11.i14.3267","article-title":"Immune checkpoint inhibitor therapy-induced autoimmune polyendocrine syndrome type II and Crohn\u2019s disease: a case report.","volume":"11","author":"Gao","year":"2023","journal-title":"World J Clin Cases"},{"key":"R8-20260811","first-page":"21","article-title":"New onset autoimmune diabetes mellitus and hypothyroidism secondary to pembrolizumab in a patient with metastatic lung cancer.","volume":"2022","author":"Cunha","year":"2022","journal-title":"Endocrinol Diabet Metab Case Rep"},{"key":"R9-20260811","doi-asserted-by":"crossref","first-page":"681","DOI":"10.3892\/etm.2022.11617","article-title":"Anti\u2011PD\u20111 immune checkpoint inhibitor inducing endocrine toxicity in a patient with advanced lung cancer: a case report and literature review.","volume":"24","author":"Bao","year":"2022","journal-title":"Exp Ther Med"},{"key":"R10-20260811","doi-asserted-by":"crossref","first-page":"e30398","DOI":"10.1097\/MD.0000000000030398","article-title":"Type 1 diabetes associated with immune checkpoint inhibitors for malignant melanoma: a case report and review of 8 cases.","volume":"101","author":"Ishiguro","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"R11-20260811","doi-asserted-by":"crossref","first-page":"e243713","DOI":"10.1136\/bcr-2021-243713","article-title":"Ipilimumab and nivolumab induced immune-related adverse events in metastatic mucosal melanoma.","volume":"14","author":"Cao","year":"2021","journal-title":"BMJ Case Rep"},{"key":"R12-20260811","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1177\/1078155220921543","article-title":"Multiple autoimmune side effects of immune checkpoint inhibitors in a patient with metastatic melanoma receiving pembrolizumab.","volume":"27","author":"Kethireddy","year":"2021","journal-title":"J Oncol Pharm Pract"},{"key":"R13-20260811","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/jdi.13212","article-title":"Simultaneous development of Graves\u2019 disease and type 1 diabetes during anti\u2010programmed cell death\u20101 therapy: a case report.","volume":"11","author":"Kurihara","year":"2020","journal-title":"J Diabetes Invest"},{"key":"R14-20260811","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.21037\/tlcr-20-408","article-title":"Development of autoimmune diabetes with severe diabetic ketoacidosis and immune-related thyroiditis secondary to durvalumab: a case report.","volume":"9","author":"Lopes","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"R15-20260811","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1080\/20009666.2020.1771126","article-title":"Nivolumab-induced autoimmune diabetes mellitus and hypothyroidism in a patient with rectal neuroendocrine tumor.","volume":"10","author":"Haque","year":"2020","journal-title":"J Commun Hospital Internal Med Perspectives"},{"key":"R16-20260811","first-page":"19","article-title":"Durvalumab-induced diabetic ketoacidosis followed by hypothyroidism.","volume":"2019","author":"Patel","year":"2019","journal-title":"Endocrinol Diabet Metab Case Rep"},{"key":"R17-20260811","first-page":"19","article-title":"Simultaneous onset of type 1 diabetes mellitus and silent thyroiditis under durvalumab treatment.","volume":"2019","author":"Meng\u00edbar","year":"2019","journal-title":"Endocrinol Diabet Metab Case Rep"},{"key":"R18-20260811","first-page":"18","article-title":"A case of pembrolizumab-induced severe DKA and hypothyroidism in a patient with metastatic melanoma.","volume":"2019","author":"Hakami","year":"2019","journal-title":"Endocrinol Diabet Metab Case Rep"},{"key":"R19-20260811","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1530\/EJE-19-0291","article-title":"Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review.","volume":"181","author":"De Filette","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"R20-20260811","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s40425-019-0713-y","article-title":"Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature.","volume":"7","author":"Gunjur","year":"2019","journal-title":"J ImmunoTher Cancer"},{"key":"R21-20260811","first-page":"19","article-title":"Clinical heterogeneity of hypophysitis secondary to PD-1\/PD-L1 blockade: insights from four cases.","volume":"2019","author":"Lupi","year":"2019","journal-title":"Endocrinol Diabet Metab Case Rep"},{"key":"R22-20260811","first-page":"18","article-title":"Nivolumab-induced fulminant diabetic ketoacidosis followed by thyroiditis.","volume":"2018","author":"Tzoulis","year":"2018","journal-title":"Endocrinol Diabet Metab Case Rep"},{"key":"R23-20260811","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1620\/tjem.244.33","article-title":"Painless thyroiditis and fulminant type 1 diabetes mellitus in a patient treated with an immune checkpoint inhibitor, nivolumab.","volume":"244","author":"Sakurai","year":"2018","journal-title":"Tohoku J Exp Med"},{"key":"R24-20260811","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00592-018-1234-8","article-title":"Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype.","volume":"56","author":"Marchand","year":"2019","journal-title":"Acta Diabetol"},{"key":"R25-20260811","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1111\/dme.13762","article-title":"Diabetes associated with immune checkpoint inhibition: presentation and management challenges.","volume":"35","author":"Galligan","year":"2018","journal-title":"Diabet Med"},{"key":"R26-20260811","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1159\/000456540","article-title":"Autoimmune diabetes and thyroiditis complicating treatment with nivolumab.","volume":"10","author":"Li","year":"2017","journal-title":"Case Rep Oncol"},{"key":"R27-20260811","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.diabet.2016.05.007","article-title":"Autoimmune diabetes superimposed on type 2 diabetes in a patient initiated on immunotherapy for lung cancer.","volume":"43","author":"Alhusseini","year":"2017","journal-title":"Diabet Metab"},{"key":"R28-20260811","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s40425-016-0196-z","article-title":"Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy.","volume":"4","author":"Lowe","year":"2016","journal-title":"J Immunother Cancer"},{"key":"R29-20260811","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s00592-016-0872-y","article-title":"Anti-programmed cell death 1 therapy triggering diabetic ketoacidosis and fulminant type 1 diabetes.","volume":"53","author":"Kong","year":"2016","journal-title":"Acta Diabetol"},{"key":"R30-20260811","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.2337\/dc15-0889","article-title":"Anti\u2013PD-1 and Anti\u2013PDL-1 monoclonal antibodies causing type 1 Diabetes.","volume":"38","author":"Mellati","year":"2015","journal-title":"Diabetes Care"},{"key":"R31-20260811","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/pedi.12148","article-title":"Autoimmune responses in T1DM: quantitative methods to understand onset, progression and prevention of disease.","volume":"15","author":"Jaberi-Douraki","year":"2014","journal-title":"Pediatr Diabetes"},{"key":"R32-20260811","doi-asserted-by":"crossref","first-page":"e3704","DOI":"10.1210\/clinem\/dgab263","article-title":"Thyroid immune-related adverse events following immune checkpoint inhibitor treatment.","volume":"106","author":"Muir","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"R33-20260811","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1111\/cas.14363","article-title":"Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors.","volume":"111","author":"Kurimoto","year":"2020","journal-title":"Cancer Sci"},{"key":"R34-20260811","doi-asserted-by":"crossref","first-page":"eabb7495","DOI":"10.1126\/scitranslmed.abb7495","article-title":"CD4+ T cells are essential for the development of destructive thyroiditis induced by anti\u2013PD-1 antibody in thyroglobulin-immunized mice.","volume":"13","author":"Yasuda","year":"2021","journal-title":"Sci Transl Med"},{"key":"R35-20260811","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1111\/cas.13800","article-title":"Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab.","volume":"109","author":"Kimbara","year":"2018","journal-title":"Cancer Sci"},{"key":"R36-20260811","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/s41416-020-0736-7","article-title":"Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study.","volume":"122","author":"Okada","year":"2020","journal-title":"Br J Cancer"},{"key":"R37-20260811","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1210\/js.2017-00432","article-title":"Patients with antithyroid antibodies are prone to develop destructive thyroiditis by nivolumab: a prospective study.","volume":"2","author":"Kobayashi","year":"2018","journal-title":"J Endocr Soc"},{"key":"R38-20260811","doi-asserted-by":"crossref","first-page":"e1056","DOI":"10.1210\/clinem\/dgad231","article-title":"Risk of thyroid dysfunction in PD-1 blockade is stratified by the pattern of TgAb and TPOAb positivity at baseline.","volume":"108","author":"Zhou","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"R39-20260811","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12902-018-0267-x","article-title":"Nivolumab-induced thyroid dysfunction lacking antithyroid antibody is frequently evoked in Japanese patients with malignant melanoma.","volume":"18","author":"Yano","year":"2018","journal-title":"BMC Endocr Disord"},{"key":"R40-20260811","doi-asserted-by":"crossref","first-page":"649863","DOI":"10.3389\/fendo.2021.649863","article-title":"Immune checkpoint inhibitors-related thyroid dysfunction: epidemiology, clinical presentation, possible pathogenesis, and management.","volume":"12","author":"Zhan","year":"2021","journal-title":"Front Endocrinol"},{"key":"R41-20260811","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1007\/s40618-019-01058-x","article-title":"Low frequency of positive antithyroid antibodies is observed in patients with thyroid dysfunction related to immune check point inhibitors.","volume":"42","author":"Mazarico","year":"2019","journal-title":"J Endocrinol Invest"},{"key":"R42-20260811","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1089\/thy.2016.0562","article-title":"Clinical features of nivolumab-induced thyroiditis: a case series study.","volume":"27","author":"Yamauchi","year":"2017","journal-title":"Thyroid"},{"key":"R43-20260811","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/j.1464-5491.2006.01951.x","article-title":"Phenotypic and genetic analyses of T-cell\u2010mediated immunoregulation in patients with Type 1 diabetes.","volume":"23","author":"Tsutsumi","year":"2006","journal-title":"Diabet Med"},{"key":"R44-20260811","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/cei.12603","article-title":"Low programmed cell death (PD-1) expression in peripheral CD4+ T cells in Japanese patients with autoimmune type 1 diabetes.","volume":"180","author":"Fujisawa","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"R45-20260811","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1084\/jem.20022125","article-title":"The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice.","volume":"198","author":"Ansari","year":"2003","journal-title":"J Exp Med"},{"key":"R46-20260811","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.2337\/db09-1135","article-title":"Deficiency in B7-H1 (PD-L1)\/PD-1 coinhibition triggers pancreatic beta-cell destruction by insulin-specific, murine CD8 T-cells.","volume":"59","author":"Rajasalu","year":"2010","journal-title":"Diabetes"},{"key":"R47-20260811","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/ni.1790","article-title":"Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR\u2013induced stop signal.","volume":"10","author":"Fife","year":"2009","journal-title":"Nat Immunol"},{"key":"R49-20260811","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/S0140-6736(17)30703-1","article-title":"Hypothyroidism.","volume":"390","author":"Chaker","year":"2017","journal-title":"Lancet"},{"key":"R50-20260811","doi-asserted-by":"crossref","first-page":"e89561","DOI":"10.1371\/journal.pone.0089561","article-title":"Blockade of the programmed death-1 (PD1) pathway undermines potent genetic protection from type 1 diabetes. Ahmad R, ed.","volume":"9","author":"Kochupurakkal","year":"2014","journal-title":"PLoS One"},{"key":"R51-20260811","first-page":"253","article-title":"Susceptibility alleles and haplotypes of human leukocyte antigen DRB1, DQA1, and DQB1 in autoimmune polyglandular syndrome type III in Japanese Population.","volume":"64","author":"Hashimoto","year":"2005","journal-title":"Horm Res"},{"key":"R52-20260811","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.2040-1124.2011.00139.x","article-title":"Class II HLA genotype in fulminant type 1 diabetes: a nationwide survey with reference to glutamic acid decarboxylase antibodies.","volume":"3","author":"Tsutsumi","year":"2012","journal-title":"J Diabetes Investig"},{"key":"R53-20260811","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1080\/19420862.2019.1654303","article-title":"Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit.","volume":"11","author":"Wang","year":"2019","journal-title":"mAbs"},{"key":"R54-20260811","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1001\/jama.2023.19918","article-title":"Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial.","volume":"330","author":"Xu","year":"2023","journal-title":"JAMA"},{"key":"R55-20260811","doi-asserted-by":"crossref","first-page":"e30456","DOI":"10.1097\/MD.0000000000030456","article-title":"New-onset type 1 diabetes mellitus as a delayed immune-related event after discontinuation of nivolumab.","volume":"101","author":"Seo","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"R56-20260811","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti\u2013programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.","volume":"28","author":"Brahmer","year":"2010","journal-title":"J Clin Oncol"},{"key":"R57-20260811","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1089\/thy.2007.0349","article-title":"Sunitinib-associated lymphocytic thyroiditis without circulating antithyroid antibodies.","volume":"18","author":"Alexandrescu","year":"2008","journal-title":"Thyroid"},{"key":"R58-20260811","first-page":"1961","article-title":"Clinical observation of apatinib-related hypothyroidism in patients with advanced malignancies.","volume":"20","author":"Xiao","year":"2020","journal-title":"Exp Ther Med"},{"key":"R59-20260811","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s12020-019-02088-4","article-title":"Thyroid profile during the alternative Sunitinib dosing 2\/1 schedule in metastatic renal cell carcinoma.","volume":"67","author":"Rizza","year":"2020","journal-title":"Endocrine"},{"key":"R60-20260811","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/cen.14135","article-title":"Thyroid disorders in programmed death 1 inhibitor\u2010treated patients: is previous therapy with tyrosine kinase inhibitors a predisposing factor?","volume":"92","author":"Sbardella","year":"2020","journal-title":"Clin Endocrinol (Oxf)"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000042490","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T08:00:22Z","timestamp":1786435222000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000042490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":59,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000042490","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,16]]}}}